Burak Ozpineci started out at ORNL working on a novel project: introducing silicon carbide into power electronics for more efficient electric vehicles. Twenty years later, the car he drives contains those same components.
As the United States transitions to clean energy, the country has an ambitious goal: cut carbon dioxide emissions in half by the year 2030, if not before. One of the solutions to help meet this challenge is found at ORNL as part of the Better Plants Program.
Scientists at ORNL and the University of Wisconsin–Madison have discovered that genetically distinct populations within the same species of fungi can produce unique mixes of secondary metabolites, which are organic compounds with applications in
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.
Consumer buy-in is key to the future of a decarbonized transportation sector in which electric vehicles largely replace today’s conventionally fueled cars and trucks.
At the Department of Energy’s Oak Ridge National Laboratory, scientists use artificial intelligence, or AI, to accelerate the discovery and development of materials for energy and information technologies.
Belinda Akpa is a chemical engineer with a talent for tackling big challenges and fostering inclusivity and diversity in the next generation of scientists.
Through a consortium of Department of Energy national laboratories, ORNL scientists are applying their expertise to provide solutions that enable the commercialization of emission-free hydrogen fuel cell technology for heavy-duty
Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.
The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.